Sunitinib is a tyrosine kinase inhibitor (TKI) inducing thyroid dysfunction, but the precise mechanism(s) involved remains to be explained, including a role of thyroid autoimmunity. The objective was to evaluate thyroid function, parameters of autoimmunity, and thyroid ultrasound findings in patients with metastatic cancer and normal thyroid function/autoimmunity before the initiation of Sunitinib therapy. This is a prospective, observational cohort study.
Thyroid dysfunction in patients with metastatic carcinoma treated with Sunitinib: is thyroid autoimmunity involved?
PANI, FABIANA;BOI, FRANCESCO;MARIOTTI, STEFANO
2015
Abstract
Sunitinib is a tyrosine kinase inhibitor (TKI) inducing thyroid dysfunction, but the precise mechanism(s) involved remains to be explained, including a role of thyroid autoimmunity. The objective was to evaluate thyroid function, parameters of autoimmunity, and thyroid ultrasound findings in patients with metastatic cancer and normal thyroid function/autoimmunity before the initiation of Sunitinib therapy. This is a prospective, observational cohort study.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Pani et al Thyroid 25_1255_2015.pdf
Solo gestori archivio
Descrizione: Articolo principale
Tipologia:
versione editoriale
Dimensione
256.37 kB
Formato
Adobe PDF
|
256.37 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
|
THY-2015-0170-Pani_1P.pdf
Solo gestori archivio
Tipologia:
versione editoriale
Dimensione
270.98 kB
Formato
Adobe PDF
|
270.98 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
|
THY-2015-0170.R3.def.pdf
accesso aperto
Tipologia:
versione pre-print
Dimensione
826.66 kB
Formato
Adobe PDF
|
826.66 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
